CRMD
CorMedix
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Buy"
RSI Overbought
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CRMD
Cormedix Inc.
A biopharmaceutical company developing therapeutic products for cardiovascular and renal diseases
300 Connell Drive, Suite 4200, Berkeley Heights, NJ 07922
--
CorMedix Inc., was incorporated in Delaware on July 28, 2006. The Company is a biopharmaceutical company focused on the development and commercialization of therapeutic products for the prevention and treatment of life-threatening diseases and conditions. The company's main focus is the commercialization of its lead product, DefenCath, in the United States. The company has licensed the development and commercialization of DefenCath worldwide. The name DefenCath is an American proprietary name approved by the U.S. Food and Drug Administration (FDA).
Company Financials
EPS
CRMD has released its 2024 Q4 earnings. EPS was reported at 0.22, versus the expected 0.14, beating expectations. The chart below visualizes how CRMD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRMD has released its 2024 Q4 earnings report, with revenue of 31.21M, reflecting a YoY change of NaN%, and net profit of 13.46M, showing a YoY change of 191.26%. The Sankey diagram below clearly presents CRMD’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
